Prelude Therapeutics Net Income Over Time
| PRLD Stock | USD 1.90 0.07 3.55% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Prelude Therapeutics Performance and Prelude Therapeutics Correlation. Will Biotechnology sector continue expanding? Could Prelude diversify its offerings? Factors like these will boost the valuation of Prelude Therapeutics. Anticipated expansion of Prelude directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Prelude Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.47) | Revenue Per Share | Quarterly Revenue Growth 1.167 | Return On Assets | Return On Equity |
The market value of Prelude Therapeutics is measured differently than its book value, which is the value of Prelude that is recorded on the company's balance sheet. Investors also form their own opinion of Prelude Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Prelude Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Prelude Therapeutics' market value can be influenced by many factors that don't directly affect Prelude Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Prelude Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Prelude Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Prelude Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income Analysis
Compare Prelude Therapeutics and related stocks such as Pyxis Oncology, Orchestra BioMed Holdings, and Enanta Pharmaceuticals Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PYXS | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (12.8 M) | (76 M) | (118 M) | (73.8 M) | (77.3 M) | (69.6 M) | (73.1 M) |
| OBIO | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (23 M) | (33.6 M) | (49.1 M) | (61 M) | (54.9 M) | (57.7 M) |
| ENTA | 7.9 M | 21.4 M | 9.6 M | 34.4 M | 79 M | 21.7 M | 17.7 M | 72 M | 46.4 M | (36.2 M) | (79 M) | (121.8 M) | (133.8 M) | (116 M) | (81.9 M) | (73.7 M) | (70 M) |
| CRBU | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (34.3 M) | (66.9 M) | (99.4 M) | (102.1 M) | (149.1 M) | (134.2 M) | (127.5 M) |
| IVA | (7.1 M) | (7.1 M) | (7.1 M) | (7.1 M) | (7.5 M) | (8.8 M) | (7 M) | (17.2 M) | (33.6 M) | (30.2 M) | (31.6 M) | (49.6 M) | (54.3 M) | (110.4 M) | (184.2 M) | (165.8 M) | (157.5 M) |
| TNYA | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (38.4 M) | (69.7 M) | (123.7 M) | (124.1 M) | (111.1 M) | (100 M) | (105 M) |
| AVTX | (10.5 M) | (10.5 M) | (10.5 M) | (13 M) | (16.1 M) | (10.5 M) | (16.5 M) | 11.9 M | (40.1 M) | (16.1 M) | (63.5 M) | (84.4 M) | (41.7 M) | (31.5 M) | (35.1 M) | (31.6 M) | (33.2 M) |
| EPRX | (4.4 M) | (4.4 M) | (4.4 M) | (4.4 M) | (4.4 M) | (4.4 M) | (4.4 M) | (4.4 M) | (13.2 M) | (7.4 M) | (4 M) | (18 M) | (18.5 M) | (28.2 M) | (36.7 M) | (33 M) | (31.4 M) |
| IMRX | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (17 M) | (33.5 M) | (50.5 M) | (53.5 M) | (61 M) | (54.9 M) | (57.7 M) |
| FHTX | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (51.1 M) | (68.8 M) | (101.3 M) | (108.9 M) | (98.4 M) | (86.6 M) | (78 M) | (81.9 M) |
Prelude Therapeutics and related stocks such as Pyxis Oncology, Orchestra BioMed Holdings, and Enanta Pharmaceuticals Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Prelude Therapeutics financial statement analysis. It represents the amount of money remaining after all of Prelude Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Prelude Therapeutics | PRLD |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 175 Innovation Boulevard, |
| Exchange | NASDAQ Exchange |
USD 1.9
Check out Prelude Therapeutics Performance and Prelude Therapeutics Correlation. For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Prelude Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.